Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres

Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case rep...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical and experimental dermatology 2023-11, Vol.48 (12), p.1376-1378
Hauptverfasser: Buffon, Stefano, Alberti Violetti, Silvia, Avallone, Gianluca, Venegoni, Luigia, Marzano, Angelo V, Mastorino, Luca, Fava, Paolo, Ribero, Simone, Quaglino, Pietro, Ortoncelli, Michela, Ferrucci, Silvia M
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case reports seem to point not only at its beneficial effects but also at a possible pathogenetic role in mycosis fungoides and Sézary syndrome. We present data collected from a cohort of 995 patients with classic or prurigo nodularis-like AD who received dupilumab and were followed longitudinally for a mean period of 25.1 months after first administration to investigate a possible correlation between dupilumab and CTCL development.
ISSN:0307-6938
1365-2230
DOI:10.1093/ced/llad277